REPORT ID 5080

United States Erythropoietin Drugs Market Report 2017

Publish Date
20-Dec-17
Pages
100
Format
Electronic (PDF)

In this report, the United States Erythropoietin Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Erythropoietin Drugs in these regions, from 2012 to 2022 (forecast).

United States Erythropoietin Drugs market competition by top manufacturers/players, with Erythropoietin Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Amgen
    Johnson & Johnson
    Hospira
    Roche
    LG Life Sciences
    Biocon
    Intas Pharmaceuticals
    Teva Pharmaceutical Industries
    Ranbaxy Laboratories
    Celltrion

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Natural Erythropoietin
    Non-natural Erythropoietin
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Anemia
    Kidney Disorders
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Erythropoietin Drugs Market Report 2017
1 Erythropoietin Drugs Overview
    1.1 Product Overview and Scope of Erythropoietin Drugs
    1.2 Classification of Erythropoietin Drugs by Product Category
        1.2.1 United States Erythropoietin Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Erythropoietin Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Natural Erythropoietin
        1.2.4 Non-natural Erythropoietin
    1.3 United States Erythropoietin Drugs Market by Application/End Users
        1.3.1 United States Erythropoietin Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Anemia
        1.3.3 Kidney Disorders
        1.3.4 Other
    1.4 United States Erythropoietin Drugs Market by Region
        1.4.1 United States Erythropoietin Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Erythropoietin Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Erythropoietin Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Erythropoietin Drugs Status and Prospect (2012-2022)
        1.4.5 New England Erythropoietin Drugs Status and Prospect (2012-2022)
        1.4.6 The South Erythropoietin Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Erythropoietin Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Erythropoietin Drugs (2012-2022)
        1.5.1 United States Erythropoietin Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Erythropoietin Drugs Revenue and Growth Rate (2012-2022)

2 United States Erythropoietin Drugs Market Competition by Players/Suppliers
    2.1 United States Erythropoietin Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Erythropoietin Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Erythropoietin Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Erythropoietin Drugs Market Competitive Situation and Trends
        2.4.1 United States Erythropoietin Drugs Market Concentration Rate
        2.4.2 United States Erythropoietin Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Erythropoietin Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Erythropoietin Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Erythropoietin Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Erythropoietin Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Erythropoietin Drugs Price by Region (2012-2017)

4 United States Erythropoietin Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Erythropoietin Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Erythropoietin Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Erythropoietin Drugs Price by Type (2012-2017)
    4.4 United States Erythropoietin Drugs Sales Growth Rate by Type (2012-2017)

5 United States Erythropoietin Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Erythropoietin Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Erythropoietin Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Erythropoietin Drugs Players/Suppliers Profiles and Sales Data
    6.1 Amgen
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Erythropoietin Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Amgen Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Johnson & Johnson
        6.2.2 Erythropoietin Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Johnson & Johnson Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Hospira
        6.3.2 Erythropoietin Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Hospira Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Roche
        6.4.2 Erythropoietin Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Roche Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 LG Life Sciences
        6.5.2 Erythropoietin Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 LG Life Sciences Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Biocon
        6.6.2 Erythropoietin Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Biocon Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Intas Pharmaceuticals
        6.7.2 Erythropoietin Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Intas Pharmaceuticals Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Teva Pharmaceutical Industries
        6.8.2 Erythropoietin Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Teva Pharmaceutical Industries Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Ranbaxy Laboratories
        6.9.2 Erythropoietin Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Ranbaxy Laboratories Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Celltrion
        6.10.2 Erythropoietin Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Celltrion Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Erythropoietin Drugs Manufacturing Cost Analysis
    7.1 Erythropoietin Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Erythropoietin Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Erythropoietin Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Erythropoietin Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Erythropoietin Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Erythropoietin Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Erythropoietin Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Erythropoietin Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Erythropoietin Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer